Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data

ypertension is a major risk factor for cardiovascular and cerebrovascular disease. The World Health Organization Global Burden of Disease Study estimates that nonoptimal blood pressure [(BP) ie, systolic BP of 115 mm Hg] is responsible annually for 7.1 million deaths and the loss of 64.3 disability-adjusted life years worldwide. he associated economic burden of hypertension is also substantial. The average annual medical care cost for individuals with hypertension has been estimated at $3900 (in year 2000 US dollars) in Canada, 2 with similar values ($3787) for the United States. The increase in medical care costs is greater for those with moderate-to-severe BP elevation (diastolic BP 104 mm Hg) than for those with mild disease. lthough a broad range of hypertension medications have been demonstrated to reduce BP, and BP control is an achievable goal, 5 reports suggest that up to two thirds of patients with hypertension are not successfully treated, that is, achieve BP control. 6 -8 According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7), BP control rates are far below the "healthy people" goal of 50% set in 2000. 9 A major (and modifiable) reason for lack of BP control is failure by patients to use medications as prescribed. 10 Appropriate use of medications includes compliance, taking medications at the prescribed frequency/ interval and dose/dosing regimen, and persistence, continuing their use for the specified treatment time period, which, in the case of hypertension therapy, is usually lifelong. Poor compliance with hypertension medications is associated with adverse health outcomes. udies have demonstrated that poor BP control is associated with greater healthcare costs. For example, in the United States, inadequate control of hypertension has been estimated to result in 40 000 cardiovascular events, 8000 cardiovascular disease deaths, and approximately $964 million in direct medical expenditures. Similarly, poor compliance and lack of persistence with BP medications are associated with increased health care costs. Whereas patients who interrupted hypertension therapy had decreased medication costs, they had greater increases in costs for other health care, mainly reflecting increased hospital costs. In other disease states, such as diabetes and hypercholesterolemia, whereas increased compliance is associated with increased medication costs (because compliant patients use more medication), overall health care costs decrease because of better disease control and lower rates of adverse outcomes. ompliance and persistence can be measured in both retrospective and prospective studies, both of which can provide data on "real world" clinical practice. However, participants in prospective evaluations may not be comparable to broader patient populations. Furthermore, prospective evaluations can potentially introduce biases, particularly in patient behaviors related to compliance and persistence. Although the use of retrospective databases avoids these problems, the lack of consistent methods for evaluation of hypertension treatment compliance and persistence in such studies makes comparisons of results among studies difficult. As presented in a review by Lopatriello et al, In addition, the lack of broadly agreed-on methods creates substantial barriers for evaluating the potential impact of compliance and persistence on BP control. Given the importance of this issue, we have developed a set of recommendations for retrospective studies assessing compliance and persistence in hypertension.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.